As of 4:14pm ET
| +0.09 / +1.44%|
The 4 analysts offering 12-month price forecasts for Merrimack Pharmaceuticals Inc have a median target of 10.50, with a high estimate of 15.00 and a low estimate of 7.00. The median estimate represents a +65.35% increase from the last price of 6.35.
The current consensus among 6 polled investment analysts is to Buy stock in Merrimack Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.